文献速递前列腺癌

镓-68 PSMA PET 在前列腺癌淋巴结转移检测中的应用:文献综述

Use of gallium-68 prostate-specific membrane antigen positron-emission tomography for detecting lymph node metastases in primary and recurrent prostate cancer and location of recurrence after radical prostatectomy: an overview of the current literature.
PubMed 文献 · BJU Int · 2019-11-29

本文综述了68Ga-PSMA PET在前列腺癌原发分期和生化复发(BCR)中的价值。在初治患者中,其检测盆腔淋巴结转移的灵敏度为33.3%-100%,特异度为80%-100%;在BCR患者中阳性预测值为70%-100%。BCR后根治性前列腺切除术(RP)患者中,PSA<0.2、0.2-0.49、0.5-<1.0 ng/mL亚组的检出率分别为11.3%-50.0%、20.0%-72.7%、25.0%-87.5%。

要点

  • 68Ga-PSMA PET对初治前列腺癌盆腔淋巴结转移特异性高(80%-100%),但灵敏度中等(33.3%-100%)。
  • BCR患者挽救性淋巴结清扫前,68Ga-PSMA PET阳性预测值达70%-100%。
  • RP后早期BCR(PSA<1.0 ng/mL)即可有较高检出率,对放疗计划有影响。

核心结论

  • 68Ga-PSMA PET对初治前列腺癌盆腔淋巴结转移特异性高,但灵敏度中等,尚不能替代淋巴结清扫。
  • 在BCR患者中,68Ga-PSMA PET检测淋巴结转移的阳性预测值很高。
  • RP后早期BCR中,68Ga-PSMA PET检出率高且影响放疗计划。

研究设计与样本

  • 通过MEDLINE、EMBASE和Science Direct检索文献,纳入9项回顾性和2项前瞻性研究评估初治分期灵敏度与特异度。
  • 纳入8项回顾性研究评估BCR患者挽救性淋巴结清扫前阳性预测值。
  • 汇总RP后BCR患者不同PSA亚组的检出率数据。

主要发现

  • 初治前列腺癌盆腔淋巴结转移检测灵敏度33.3%-100%,特异度80%-100%。
  • BCR患者挽救性淋巴结清扫前阳性预测值70%-100%。
  • RP后BCR患者PSA<0.2 ng/mL组检出率11.3%-50.0%,0.2-0.49 ng/mL组20.0%-72.7%,0.5-<1.0 ng/mL组25.0%-87.5%。

临床怎么用

  • 68Ga-PSMA PET可用于初治前列腺癌盆腔淋巴结转移的无创评估,但阴性结果不能排除转移。
  • 在BCR患者中,68Ga-PSMA PET阳性结果可靠预测淋巴结转移,可指导挽救性治疗。
  • RP后早期BCR(PSA<1.0 ng/mL)行68Ga-PSMA PET检出率高,有助于制定放疗计划。

局限性

  • 纳入研究多为回顾性,证据等级有限。
  • 灵敏度范围宽,异质性可能较大。
  • 缺乏大规模前瞻性研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To review the literature to determine the sensitivity and specificity of gallium-68 prostate-specific membrane antigen (68 Ga-PSMA) positron-emission tomography (PET) for detecting pelvic lymph node metastases in patients with primary prostate cancer (PCa), and the positive predictive value in patients with biochemical recurrence (BCR) after initial curative treatment, and, in addition, to determine the detection rate and management impact of 68 Ga-PSMA PET in patients with BCR after radical prostatectomy (RP). MATERIALS AND METHODS: We performed a comprehensive literature search. Search terms used in MEDLINE, EMBASE and Science Direct were '(PSMA, 68 Ga-PSMA, 68 Gallium-PSMA, Ga-68-PSMA or prostate-specific membrane antigen)' and '(histology, lymph node, staging, sensitivity, specificity, positive predictive value, recurrence, recurrent or detection)'. Relevant abstracts were reviewed and full-text articles obtained where possible. References to and from obtained articles were searched to identify further relevant articles. RESULTS: Nine retrospective and two prospective studies described the sensitivity and specificity of 68 Ga-PSMA PET for detecting pelvic lymph node metastases before initial treatment, which ranged from 33.3% to 100% and 80% to 100%, respectively. In eight retrospective studies, the positive predictive value of 68 Ga-PSMA PET in patients with BCR before salvage lymph node dissection ranged from 70% to 100%. The detection rate of 68 Ga-PSMA PET in patients with BCR after RP in the PSA subgroups <0.2 ng/mL, 0.2-0.49 ng/mL and 0.5 to <1.0 ng/mL ranged from 11.3% to 50.0%, 20.0% to 72.7% and 25.0% to 87.5%, respectively. CONCLUSION: The review results showed that 68 Ga-PSMA PET had a high specificity for the detection of pelvic lymph node metastases in primary PCa. Furthermore, 68 Ga-PSMA PET had a very high positive predictive value in detecting lymph node metastases in patients with BCR. By contrast, sensitivity was only moderate; therefore, based on the currently available literature, 68 Ga-PSMA PET cannot yet replace pelvic lymph node dissection to exclude lymph node metastases. In the salvage phase, 68 Ga-PSMA PET had both a high detection rate and impact on radiotherapy planning in early BCR after RP.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Luiting HB, van Leeuwen PJ, Busstra MB, et al. Use of gallium-68 prostate-specific membrane antigen positron-emission tomography for detecting lymph node metastases in primary and recurrent prostate cancer and location of recurrence after radical prostatectomy: an overview of the current literature. BJU Int. 2019. PMID: 31680398. doi:10.1111/bju.14944

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。